Download pdf
Scutellaria Baicalensis Georgi in the Suppression of Colorectal Cancer Through Modulation of the Intestinal Flora
- 1 Institute of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210009, China
* Author to whom correspondence should be addressed.
Abstract
Colorectal cancer (CRC) is a common malignant tumor worldwide, and its incidence and mortality are growing year by year. In recent years, the beginning and course of CRC are directly linked to intestinal flora imbalance, according to an increasing number of research.Therefore, finding a unique treatment approach and direction that can regulate the intestinal flora is therefore urgently needed. Traditional Chinese medicine as an adjuvant therapy for CRC has the characteristics of multi-targets, multi-levels, multi-links, and overall regulation, and it has significant advantages in the prevention and management of CRC.Scutellaria baicalensis Georgi (SBG), as one of the main drugs in the utilisation of traditional Chinese medicine as an adjuvant therapy for CRC, has been widely studied and recognised. Studies have shown that SBG and its active ingredients can aid in the prevention and management of CRC by regulating the intestinal flora, improving the imbalance of the flora, inhibiting the proliferation of harmful microorganisms, and enhancing the function of advantageous microorganisms. In addition, scutellaria can also inhibit the incidence and development of CRC by inhibiting inflammatory response, inducing apoptosis of cancer cells and blocking signaling pathways
Keywords
Scutellaria baicalensis Georgi, Intestinal flora, Colorectal cancer, Anti-tumour mechanism of action
[1]. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. CA: a cancer journal for clinicians. 2020 May;70(3):145-64.
[2]. Gagnière J, Raisch J, Veziant J, Barnich N, Bonnet R, Buc E, Bringer MA, Pezet D, Bonnet M. Gut microbiota imbalance and colorectal cancer. World journal of gastroenterology. 2016 Jan 14;22(2):501.
[3]. Zhu Q, Gao R, Wu W, Qin H. The role of gut microbiota in the pathogenesis of colorectal cancer. Tumor Biology. 2013 Jun;34:1285-300.
[4]. Ruotong W, Daofei L, Feng X, et al. Progress in the study of the composition and action of Scutellaria baicalensis[J]. Guangzhou Chemical Industry,2021,49(22):17-19.
[5]. Cheng Y, Ling Z, Li L. The intestinal microbiota and colorectal cancer. Frontiers in immunology. 2020 Nov 30;11:615056.
[6]. Genua F, Raghunathan V, Jenab M, Gallagher WM, Hughes DJ. The role of gut barrier dysfunction and microbiome dysbiosis in colorectal cancer development. Frontiers in Oncology. 2021 Apr 15;11:626349.
[7]. Shennong Ben Cao Jing. Ancient classics of Chinese medicine.
[8]. Yongjie D,Yuqiao G,Dan S. Progress in the study of the anticolorectal cancer effects of heat-clearing and detoxifying herbs. Asia-Pacific Traditional Medicine, 2019, 15(5):197-20
[9]. Haoran L,Enxin Z . Screening of key genes for inflammatory bowel disease-colorectal cancer transformation and Chinese medicines for prevention and treatment based on biosignature analysis. New Chinese Medicines and Clinical Pharmacology, 2022, 33(3):372-379.
[10]. Wang Y, Cai Y, Li F, Zhang M, Wu Y, Dai Y, Zheng F, Yue H, Bai B. Effects of Scutellaria baicalensis Georgi. on intestinal flora in rats with spleen deficiency and damp-heat. Journal of pharmaceutical and biomedical analysis. 2022 Aug 5;217:114831.
[11]. WANG Rui, WANG Lin, WEI Guang-yi, LIU Nan-nan, ZHANG Li, WANG Shu-mei, DU Guan-hua. The effect and mechanism of baicalein on regulating gut microbiota and improving chemotherapy-induced intestinal mucositis in mice. Acta Pharmaceutica Sinica, 2020, 55(5): 868-876.
[12]. Luo X, YU Z, Deng C, Zhang J, Wang Z, Dou W. Effect and mechanism of baicalein on 2, 4, 6-trinitrobenzene sulfonic acid-induced experimental colitis of mice. Chinese Journal of Pharmacology and Toxicology. 2017:541-6.
[13]. Yu Z, Xiaojia L, Wei Z, Jian Z, Aiting W, Jing W, Lin Y, Bangwei C, Dan Y. Baicalin circumvents anti-PD-1 resistance by regulating the gut microbiota metabolite short-chain fatty acids. Pharmacological Research. 2024 Jan 1;199:107033.
[14]. Zhang L, Miao C, Wang Z, Guan X, Ma Y, Song J, Shen S, Song H, Li M, Liu C. Preparation and characterisation of baicalin magnesium and its protective effect in ulcerative colitis via gut microbiota-bile acid axis modulation. Phytomedicine. 2024 Apr 1;126:155416.
[15]. Honggang Chi,Study on the regulatory mechanism of IL-22 in the transformation of intestinal physiological inflammation to ulcerative colitis and the intervention effect of Scutellaria baicalensis soup. Guangdong Province, Guangdong Medical University, 2019-09-28.
Cite this article
Qiu,M. (2025). Scutellaria Baicalensis Georgi in the Suppression of Colorectal Cancer Through Modulation of the Intestinal Flora. Theoretical and Natural Science,111,10-16.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of ICBioMed 2025 Symposium: AI for Healthcare: Advanced Medical Data Analytics and Smart Rehabilitation
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).